Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2021 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology

Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with...